Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BMS-986253 + Nivolumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BMS-986253||HuMax-IL8|MDX 018|MDX-018|BMS986253|BMS- 86253||BMS-986253 (HuMax-IL8) is a monoclonal antibody that targets interleukin-8 (CXCL8, IL8) to prevent activation of the receptors, CXCR1 and CXCR2, in effort to prevent immune escape and tumor progression (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3091-3091).|
|Nivolumab||Opdivo||MDX-1106|BMS-936558||Immune Checkpoint Inhibitor 136 PD-L1/PD-1 antibody 79||Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer, small cell lung cancer, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) in patients with melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, in combination with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations, in combination with Cabometyx (cabozantinib) in patients with advanced renal cell carcinoma, and in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04848116||Phase II||Cabiralizumab + Nivolumab BMS-986253 + Nivolumab Nivolumab||Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (Spark2)||Recruiting||USA||0|
|NCT04123379||Phase II||BMS-813160 + Nivolumab Nivolumab BMS-986253 + Nivolumab||Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)||Recruiting||USA||0|
|NCT03400332||Phase Ib/II||BMS-986253 + Nivolumab||An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers||Recruiting||USA | CAN||6|
|NCT04050462||Phase II||BMS-986253 + Nivolumab Nivolumab Cabiralizumab + Nivolumab||A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients||Recruiting||USA||0|
|NCT04572451||Phase I||BMS-986253 + Nivolumab||Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors||Recruiting||USA||0|